Avadel Pharmaceuticals (AVDL) Common Equity (2016 - 2022)
Historic Common Equity for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to -$12.4 million.
- Avadel Pharmaceuticals' Common Equity fell 11257.11% to -$12.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$12.4 million, marking a year-over-year decrease of 11257.11%. This contributed to the annual value of $78.2 million for FY2021, which is 5178.04% down from last year.
- According to the latest figures from Q3 2022, Avadel Pharmaceuticals' Common Equity is -$12.4 million, which was down 11257.11% from -$3.3 million recorded in Q2 2022.
- Avadel Pharmaceuticals' Common Equity's 5-year high stood at $182.1 million during Q2 2020, with a 5-year trough of -$29.2 million in Q4 2019.
- In the last 5 years, Avadel Pharmaceuticals' Common Equity had a median value of $55.2 million in 2022 and averaged $56.2 million.
- As far as peak fluctuations go, Avadel Pharmaceuticals' Common Equity crashed by 115032.37% in 2019, and later skyrocketed by 112449.79% in 2020.
- Avadel Pharmaceuticals' Common Equity (Quarter) stood at $2.8 million in 2018, then tumbled by 1150.32% to -$29.2 million in 2019, then surged by 655.72% to $162.3 million in 2020, then plummeted by 51.78% to $78.2 million in 2021, then crashed by 115.9% to -$12.4 million in 2022.
- Its last three reported values are -$12.4 million in Q3 2022, -$3.3 million for Q2 2022, and $55.2 million during Q1 2022.